SCHEMBL5070097

SCHEMBL5070097

CCCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCCC)Cc1ccc(OC)c(OC)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.48
GAA P10253 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
C5AR1 P21730 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.41
ALDH1A1 P00352 2/20 0.41
HTT P42858 1/20 0.41
ABCC1 P33527 1/20 0.39
HRH3 Q9Y5N1 1/20 0.38
DRD2 P14416 1/20 0.38
DRD3 P35462 1/20 0.38
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
KMT2A Q03164 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
SMPD1 P17405 1/20 0.37
BCHE P06276 1/20 0.37
KDM4E B2RXH2 1/20 0.37
CYP3A4 P08684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649655 0.97 C5AR1 (0.47) TP53GAASMN1; SMN2C5AR1L3MBTL1
SCHEMBL5137288 0.94 C5AR1 (0.43) TP53GAASMN1; SMN2C5AR1ALDH1A1
SCHEMBL5135188 0.93 MEN1 (0.42) TP53GAASMN1; SMN2C5AR1L3MBTL1
SCHEMBL5136877 0.92 C5AR1 (0.43) TP53GAASMN1; SMN2C5AR1L3MBTL1
SCHEMBL648191 0.91 C5AR1 (0.46) TP53GAASMN1; SMN2C5AR1ALDH1A1
SCHEMBL651343 0.91 C5AR1 (0.47) TP53GAASMN1; SMN2C5AR1L3MBTL1
SCHEMBL5134880 0.90 MEN1 (0.43) TP53GAASMN1; SMN2C5AR1L3MBTL1
SCHEMBL5137523 0.90 MEN1 (0.47) TP53GAASMN1; SMN2C5AR1L3MBTL1
SCHEMBL649485 0.89 C5AR1 (0.45) TP53GAASMN1; SMN2C5AR1ALDH1A1
SCHEMBL1912916 0.89 C5AR1 (0.47) TP53GAASMN1; SMN2C5AR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed